Royalty Pharma plc

NasdaqGS:RPRX Lagerbericht

Marktkapitalisierung: US$32.4b

Royalty Pharma Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Royalty Pharma hat ein Gesamteigenkapital von $9.9B und eine Gesamtverschuldung von $9.0B, wodurch sich der Verschuldungsgrad auf 90.1% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen $19.8B bzw. $9.9B. Royalty Pharma Das EBIT des Unternehmens beträgt $1.7B, so dass der Zinsdeckungsgrad 5.4 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von $608.3M.

Wichtige Informationen

90.13%

Verhältnis von Schulden zu Eigenkapital

US$8.96b

Verschuldung

Zinsdeckungsgrad5.4x
BargeldUS$608.30m
EigenkapitalUS$9.94b
GesamtverbindlichkeitenUS$9.88b
GesamtvermögenUS$19.82b

Jüngste Berichte zur Finanzlage

Keine Aktualisierungen

Recent updates

Narrativ-Update • Jun 19

RPRX: Royalty Deals And Buybacks Will Support Long Term Stock Upside

Analysts have raised their price target for Royalty Pharma stock to $66.00 from $60.61, citing updated views on fair value, discount rate, expected revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent Street research on Royalty Pharma points to a cluster of higher price targets and supportive commentary around valuation, execution, and growth prospects.
Narrativ-Update • Jun 03

RPRX: Royalty Deals And Buybacks Will Shape Balanced Future Returns

Analysts have lifted their average price target for Royalty Pharma to about $59, up from roughly $52, citing updated views on long term revenue potential, higher expected profitability, and a lower assumed future P/E multiple. These factors are reflected in recent target increases from firms like Morgan Stanley and UBS, as well as positive commentary around the $250m Zymeworks financing deal.
Seeking Alpha • May 16

Royalty Pharma: Strong Execution, Expanding Pipeline And More Firepower Ahead

Summary Portfolio Receipts increased 10% to $925 million, while Royalty Receipts grew 13% to $887 million. Q1 confirmed a supportive, broad-based momentum. Management's 2030 Portfolio Receipts target of $4.7 billion increasingly appears conservative. Recent funding agreements with Johnson & Johnson, alongside prior collaborations with Biogen, Merck, and Teva, strengthen Royalty Pharma’s positioning. Capital flexibility and buybacks remain meaningful tailwinds. We remain buyers. Read the full article on Seeking Alpha
Narrativ-Update • May 02

RPRX: Royalty Deals And Buybacks Will Shape Balanced Forward Outlook

Analysts have raised their blended price target on Royalty Pharma by several dollars to around the mid $40s, citing refined models that factor in slightly higher projected revenue growth, modestly lower profit margins, and continued benefits from recent royalty and financing deals such as the $250m Zymeworks agreement. Analyst Commentary Recent research on Royalty Pharma centers on how the updated price targets line up with the company’s deal pipeline, especially the $250m Zymeworks transaction.
Narrativ-Update • Apr 17

RPRX: Diversified Royalty Portfolio And Recent Deals Will Support Future Upside

Analysts have nudged their price targets for Royalty Pharma modestly higher, with the average fair value estimate moving from about $59.28 to $60.61. They point to the company's diversified royalty portfolio, favorable deal terms such as the $250m Zymeworks financing, and the broader growth of the biopharma royalty market.
Narrativ-Update • Apr 03

RPRX: Royalty Deals And Dividend Policy Will Shape Balanced Forward Outlook

Analysts have raised the fair value estimate for Royalty Pharma to $46.00 from $40.86, citing updated models that reflect perceived strengths in its biopharma royalty exposure, portfolio diversification, and recent deal activity. Analyst Commentary Recent Street research around Royalty Pharma highlights both constructive and cautious views, giving you a mixed picture of how professionals are thinking about the stock.
Narrativ-Update • Mar 19

RPRX: Royalty Deals And Buybacks Will Support Future Upside

Analysts have lifted their price target on Royalty Pharma to $51.56 from $51.00, citing updated Street views on its biopharma royalty exposure and recent deal activity as key supports for the revised fair value estimate. Analyst Commentary Recent Street commentary on Royalty Pharma highlights a mix of optimism around its royalty portfolio and business model, alongside some areas where investors may want to stay cautious on execution and deal risk.
Narrativ-Update • Mar 05

RPRX: Royalty Platform And Portfolio Diversification Will Drive Future Upside Potential

Analysts have nudged their targets higher on Royalty Pharma, with the consensus fair value estimate moving from $56.00 to about $59.28. They cite expectations for the company to benefit from growth in the biopharma royalty market, differentiation from competitors, and a more diversified portfolio.
Narrativ-Update • Feb 19

RPRX: Higher P/E Expectations And Buybacks Will Support Future Upside

Analysts have lifted their average price target on Royalty Pharma from about $46 to roughly $51, citing updated assumptions for fair value, discount rate, growth, margins, and a higher future P/E multiple as key drivers behind the move. Analyst Commentary Recent research coverage on Royalty Pharma has centered on refreshed models for fair value and updated assumptions around discount rates, growth, margins, and future P/E multiples.
Analyseartikel • Feb 11

Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.235

Royalty Pharma plc's ( NASDAQ:RPRX ) dividend will be increasing from last year's payment of the same period to $0.235...
Narrativ-Update • Feb 05

RPRX: Pending XenoTherapeutics Deal And Dividend Increase Will Shape Near-Term Returns

Analysts have raised their price targets on Royalty Pharma by about $2 to an updated fair value of US$40.86, citing slightly higher long term revenue growth assumptions, a modestly higher future P/E multiple, and largely unchanged discount rate and profit margin inputs. Analyst Commentary Recent research on Royalty Pharma has been mixed, with some firms updating ratings and price targets around the company’s agreed acquisition by XenoTherapeutics at an estimated US$1.82 per share.
Analyseartikel • Jan 22

Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

Royalty Pharma plc's ( NASDAQ:RPRX ) dividend will be increasing from last year's payment of the same period to $0.235...
Narrativ-Update • Jan 21

RPRX: Pending XenoTherapeutics Deal And Hold Downgrade Will Limit Near-Term Upside

Analysts have trimmed their price expectations for Royalty Pharma, citing a revised fair value of $38.00 per share. This reflects updated views on revenue growth, profit margins, and future P/E multiples following the announced acquisition by XenoTherapeutics and the recent downgrade to Hold.
Narrativ-Update • Jan 07

RPRX: Agreed XenoTherapeutics Deal Will Highlight Upside In Royalty Portfolio Earnings Power

Analysts have nudged their fair value target for Royalty Pharma up to US$56.00 from US$55.00. This reflects updated assumptions on slower revenue growth, higher margins and a lower future P/E, while also factoring in the recent downgrade to Hold following the agreed acquisition by XenoTherapeutics at an estimated US$1.82 per share.
Narrativ-Update • Dec 15

RPRX Pending XenoTherapeutics Deal Will Anchor Shares Near Buyout Price

Analysts have nudged their price target on Royalty Pharma up by $1, to $38. This reflects modestly stronger revenue growth assumptions, offset by a slightly higher discount rate and lower projected profit margins, and incorporates the limited upside they see given the pending acquisition by XenoTherapeutics.
Narrativ-Update • Dec 01

RPRX: Share Buybacks Will Drive Value Upon Acquisition Completion

Analysts have revised Royalty Pharma's price target slightly upward from $45.54 to $45.98. They note that the pending acquisition by XenoTherapeutics has reduced uncertainty around the company’s valuation.
Narrativ-Update • Nov 17

RPRX: Share Buybacks And Acquisition Will Drive Outperformance After Downgrade

Analysts have raised Royalty Pharma's price target from $44.10 to $45.54, reflecting updated expectations for revenue growth. However, profit margins are anticipated to decrease following recent acquisition developments.
Narrativ-Update • Nov 02

RPRX: Upcoming Licensing Deals And Share Buybacks Will Drive Long-Term Upside

Narrative Update on Royalty Pharma: Analyst Price Target Revision Analysts have lowered their fair value estimate for Royalty Pharma from $44.86 to $44.10 per share. This revision is based on updated modeling of revenue growth and profit margins.
Narrativ-Update • Sep 04

Emerging Therapies And Licensing Will Expand Royalty Opportunities

Analysts maintain a positive outlook for Royalty Pharma, citing resilience amid sector underperformance, limited exposure to policy and macroeconomic risks, and anticipated seasonal strength, with the consensus price target unchanged at $43.27. Analyst Commentary Bullish analysts expect Q2 to be seasonally strong for large biopharma companies, supporting near-term performance.
Analyseartikel • Jul 06

Benign Growth For Royalty Pharma plc (NASDAQ:RPRX) Underpins Its Share Price

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...
Seeking Alpha • Feb 13

Royalty Pharma: Delivering Growth With A Positive Story Ahead

Summary Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million, which demonstrate solid performance. MorphoSys bond redeployment further enhances higher-returning royalty opportunities. The company has a solid balance sheet with $1.4 billion in cash equivalents, which is worth considering. RPRX's valuation remains compelling, with a double-digit total yield (via buyback and dividend). Read the full article on Seeking Alpha
Seeking Alpha • Jan 15

Royalty Pharma: Key Strategic Updates To Be Priced In

Summary Key strategic updates include acquiring RP Management LLC, simplifying the corporate structure, reducing costs, and enhancing shareholder alignment. A new $3 billion share repurchase program and a 5% dividend increase highlight strong capital allocation, maintaining financial flexibility and an investment-grade credit rating. The valuation remains compelling, with a 30% upside. Anticipated savings and buybacks suggest further EPS growth, reinforcing our overweight rating. Read the full article on Seeking Alpha
Seeking Alpha • Nov 09

Royalty Pharma: Massive Opportunity Ahead

Summary Royalty Pharma's Q3 results met expectations, with a modest 2024 outlook increase, driven by strong portfolio performance and new royalty acquisitions. The CF franchise remains a key cash cow despite challenges, with Vertex's Venza triple development posing potential headwinds. With a compelling valuation, a $1 billion buyback, and a supportive pipeline, Royalty Pharma is a strong buy. Read the full article on Seeking Alpha

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: RPRXDie kurzfristigen Aktiva des Unternehmens ($1.4B) übersteigen seine kurzfristigen Passiva ($535.7M).

Langfristige Verbindlichkeiten: RPRXDie kurzfristigen Vermögenswerte des Unternehmens ($1.4B) decken seine langfristigen Verbindlichkeiten ($9.3B) nicht.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: RPRXDie Nettoverschuldung im Verhältnis zum Eigenkapital (84%) wird als hoch angesehen.

Schulden abbauen: RPRXDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 59.2% auf 90.1% gestiegen.

Schuldendeckung: RPRXDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (29.2%).

Zinsdeckung: RPRXDie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (5.4x Coverage) gut gedeckt.

Bilanz

Entdecken Sie finanziell stabile Unternehmen

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/06/29 07:31
Aktienkurs zum Tagesende2026/06/29 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Royalty Pharma plc wird von 14 Analysten beobachtet. 5 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Jason Matthew GerberryBofA Global Research
Geoffrey MeachamCitigroup Inc
Prem ChulakiCrispIdea